Disappointing Bydureon EXSCEL Outcomes Data May Raise Stakes For Victoza
Executive Summary
AstraZeneca's EXSCEL study could have created confidence in a GLP-1 class-wide outcomes benefit, but instead it has raised questions about whether differences in trial results boil down to trial design.
You may also be interested in...
The Year's Clinical Trials In Review: Big Hits In 2017
Scrip takes a trip back through the highs of drug development, looking at successes including positive cardiovascular outcomes studies for cholesterol drugs, advances in cancer and breakthroughs in hemophilia.
Novo Nordisk Says More To Victoza Outcomes Benefit Than A GLP-1 Class Effect
Novo Nordisk's ESC satellite symposium on heels of FDA approval of CV event prevention claim for Victoza highlights differences compared to Sanofi's competing Lyxumia, which failed an outcomes study.
Advantage Novo As Victoza Gets CV Benefit Okay in Europe
Victoza is the only drug in the GLP-1 class in Europe to have a label that includes the prevention of CV events (and only the second antidiabetic after Boehringer Ingelheim/Lilly’s SGLT2 inhibitor Jardiance) which will help slow down market share loss to Lilly's Trulicity.